金斯瑞生物科技行使可转债权 持有Probio Cayman股份增至71.72%
财中社12月20日电金斯瑞生物科技（01548）发布公告，宣布公司行使其间接非全资附属公司Probio Technology Limited（“Probio Cayman”）发行的可转换债券的转换权。根据2021年8月24日的可转换债券文书及其修订协议，公司将7000万美元的可转换债券转换为1.06亿股Probio Cayman普通股，转换价为每股0.66美元。
转换完成后，公司将直接和间接拥有Probio Cayman约71.72%的股份。转换后Probio Cayman的股权结构显示，公司持有的Probio Cayman普通股占6.64%，而通过全资附属公司Probio BVI间接持有65.08%。此外，Probio Cayman的员工持股计划可发行最多3.11亿股股份，截至公告日尚未配发。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10